-
Je něco špatně v tomto záznamu ?
Chitosan derivatives with antimicrobial, antitumour and antioxidant activities--a review
Jarmila Vinšová, Eva Vavríková
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Grantová podpora
NS10367
MZ0
CEP - Centrální evidence projektů
- MeSH
- antiinfekční látky chemie farmakologie terapeutické užití MeSH
- antioxidancia chemie farmakologie terapeutické užití MeSH
- antitumorózní látky chemie farmakologie terapeutické užití MeSH
- chitosan analogy a deriváty chemie farmakologie terapeutické užití MeSH
- lidé MeSH
- molekulární struktura MeSH
- racionální návrh léčiv MeSH
- vztahy mezi strukturou a aktivitou MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Chitosan is a linear polysaccharide with a good biodegradability, biocompatibility, and no toxicity, which provide it with huge potential for future development. The chitosan molecule appears to be a suitable polymeric complex for many biomedical applications. This review gathers current findings on the antibacterial, antifungal, antitumour and antioxidant activities of chitosan derivatives and concurs with our previous review presenting data collected up to 2008. Antibacterial activity is based on molecular weight, the degree of deacetylation, the type of substitutents, which can be cationic or easily form cations, and the type of bacterium. In general, high molecular weight chitosan cannot pass through cell membranes and forms a film that protects cells against nutrient transport through the microbial cell membrane. Low molecular weight chitosan derivatives are water soluble and can better incorporate the active molecule into the cell. Gram-negative bacteria, often represented by Escherichia coli, have an anionic bacterial surface on which cationic chitosan derivatives interact electrostatically. Thus, many chitosan conjugates have cationic components such as ammonium, pyridinium or piperazinium substituents introduced into their molecules to increase their positive charge. Gram-positive bacteria like Staphylococcus aureus are inhibited by the binding of lower molecular weight chitosan derivatives to DNA or RNA. Chitosan nanoparticles exhibit an increase in loading capacity and efficacy. Antitumour active compounds such as doxorubicin, paclitaxel, docetaxel and norcantharidin are used as drug carriers. It is evident that chitosan, with its low molecular weight, is a useful carrier for molecular drugs requiring targeted delivery. The antioxidant scavenging activity of chitosan has been established by the strong hydrogen-donating ability of chitosan. The low molecular weight and greater degree of quarternization have a positive influence on the antioxidant activity of chitosan. Phenolic and polyphenolic compounds with antioxidant effects are condensed with chitosan to form mutual prodrugs.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12022205
- 003
- CZ-PrNML
- 005
- 20160308083213.0
- 007
- ta
- 008
- 120806s2011 ne f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.2174/138161211798194468 $2 doi
- 035 __
- $a (PubMed)22074429
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Vinšová, Jarmila, $u Charles University, Faculty of Pharmacy, Department of Inorganic and Organic Chemistry, Hradec Králové, Czech Republic. vinsova@faf.cuni.cz $d 1951- $7 nlk19990073991
- 245 10
- $a Chitosan derivatives with antimicrobial, antitumour and antioxidant activities--a review / $c Jarmila Vinšová, Eva Vavríková
- 520 9_
- $a Chitosan is a linear polysaccharide with a good biodegradability, biocompatibility, and no toxicity, which provide it with huge potential for future development. The chitosan molecule appears to be a suitable polymeric complex for many biomedical applications. This review gathers current findings on the antibacterial, antifungal, antitumour and antioxidant activities of chitosan derivatives and concurs with our previous review presenting data collected up to 2008. Antibacterial activity is based on molecular weight, the degree of deacetylation, the type of substitutents, which can be cationic or easily form cations, and the type of bacterium. In general, high molecular weight chitosan cannot pass through cell membranes and forms a film that protects cells against nutrient transport through the microbial cell membrane. Low molecular weight chitosan derivatives are water soluble and can better incorporate the active molecule into the cell. Gram-negative bacteria, often represented by Escherichia coli, have an anionic bacterial surface on which cationic chitosan derivatives interact electrostatically. Thus, many chitosan conjugates have cationic components such as ammonium, pyridinium or piperazinium substituents introduced into their molecules to increase their positive charge. Gram-positive bacteria like Staphylococcus aureus are inhibited by the binding of lower molecular weight chitosan derivatives to DNA or RNA. Chitosan nanoparticles exhibit an increase in loading capacity and efficacy. Antitumour active compounds such as doxorubicin, paclitaxel, docetaxel and norcantharidin are used as drug carriers. It is evident that chitosan, with its low molecular weight, is a useful carrier for molecular drugs requiring targeted delivery. The antioxidant scavenging activity of chitosan has been established by the strong hydrogen-donating ability of chitosan. The low molecular weight and greater degree of quarternization have a positive influence on the antioxidant activity of chitosan. Phenolic and polyphenolic compounds with antioxidant effects are condensed with chitosan to form mutual prodrugs.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antiinfekční látky $x chemie $x farmakologie $x terapeutické užití $7 D000890
- 650 _2
- $a antitumorózní látky $x chemie $x farmakologie $x terapeutické užití $7 D000970
- 650 _2
- $a antioxidancia $x chemie $x farmakologie $x terapeutické užití $7 D000975
- 650 _2
- $a chitosan $x analogy a deriváty $x chemie $x farmakologie $x terapeutické užití $7 D048271
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Vavříková, Eva $u Charles University, Faculty of Pharmacy, Department of Inorganic and Organic Chemistry, Hradec Králové, Czech Republic $7 xx0126311
- 773 0_
- $w MED00007893 $t Current pharmaceutical design $x 1873-4286 $g Roč. 17, č. 32 (2011), s. 3596-3607
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22074429 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120806 $b ABA008
- 991 __
- $a 20160308083228 $b ABA008
- 999 __
- $a ok $b bmc $g 944118 $s 779502
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 17 $c 32 $d 3596-3607 $i 1873-4286 $m Current pharmaceutical design $n Curr Pharm Des $x MED00007893
- GRA __
- $a NS10367 $p MZ0
- LZP __
- $b NLK111 $a Pubmed-20120806/12/01